Sun Pharmaceutical Industries Ltd.
Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai - 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
www.sunpharma.com
CIN : L24230GJ1993PLC019050

October 21, 2015

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051.

BSE Limited.,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.

Dear Sirs,

Sub : Notice for Settlement Agreement for Patent Litigation entered into with Acorda Therapeutics, Inc

This is to inform that Sun Pharmaceutical Industries Ltd, along with its subsidiary (Sun Pharma) has entered into a settlement agreement with Acorda Therapeutics, Inc. to resolve the pending patent litigation involving Ampyra® (dalfampridine) Extended-Release Tablets in the US. The pending patent litigation was filed by Acorda Therapeutics in the U.S. District Court for the District of Delaware in response to Sun Pharma's submission of an Abbreviated New Drug Application ("ANDA") to the U.S. Food and Drug Administration ("FDA"), seeking marketing approval for a generic version of Ampyra®. As a result of the settlement agreement, Sun Pharma will be permitted to market a generic version of Ampyra® in the United States at a specified date in 2027, or potentially earlier under certain circumstances. Details of the settlement are confidential, and the parties will submit the agreement to the Federal Trade Commission and the Department of Justice, as required by federal law. As per IMS MAT July 2015, Ampyra® recorded annual sales of approximately US$ 325 million in the US.

This is for your information and record.

Thanking you,

Yours faithfully,
For Sun Pharmaceutical Industries Ltd

A I Bhuta

Ashok Bhuta
Compliance Officer